A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Phase 1

Terminated

• Conditions: Kidney Neoplasms; Renal Cell Carcinoma (RCC); Clear-cell Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Ovarian Clear Cell Carcinoma
• Interventions: Drug: CDX-014

• Registration Number: NCT02837991
• Lead Sponsor: Celldex Therapeutics

Brief Summary

This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).

Detailed Description

CDX-014 is an antibody-drug conjugate that binds to a protein called TIM-1, which is found on a high percentage of kidney cells that are clear or papillary and ovarian cancer cells that are clear cell.

The study will enroll patients with advanced or metastatic renal cell carcinoma and ovarian clear cell carcinoma to determine the safety and efficacy of CDX-014.

This study will include a Dose-Escalation Phase followed by a Cohort Expansion Phase

All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.

Study Timeline

• Study Start: 2016-06
• Study First Submitted: 2016-07-13
• Study First Submitted QC: 2016-07-15
• Study First Posted: 2016-07-20
• Status Verified: 2018-11
• Primary Completion: 2018-11-16
• Study Completion: 2018-11-16
• Last Update Submitted: 2020-06-02
• Last Update Posted: 2020-06-04

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

1. Histologically confirmed diagnosis of advanced or metastatic clear cell or papillary renal cell carcinoma or histologically confirmed clear cell ovarian carcinoma.
2. For RCC, at least two prior anticancer regimens (one must be a VEGF-targeted TKI), or are otherwise inappropriate candidates for all approved therapies. For OCCC, at least one line of prior therapy with a platinum and taxane regimen.
3. Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
4. Measureable (target) disease.
5. Must have available tumor tissue for TIM-1 expression testing
6. Life expectancy ≥ 3 months
7. If of childbearing potential (male or female), agrees to use effective contraception during study treatment and for at least 6 months following last treatment dose.

Exclusion Criteria

1. Prior therapy containing MMAE
2. Any prior cytotoxic chemotherapy regimen, including antibody drug conjugates for RCC or cytotoxic chemotherapy within 3 weeks of study treatment for OCCC
3. Tyrosine kinase inhibitor (TKI) therapy within 2 weeks or at least 5 half-lives (whichever is longer) prior to planned start of study treatment.
4. Monoclonal antibody therapy within 4 weeks prior to the planned start of study treatment.
5. Radiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed up to 2 weeks prior to study treatment start).
6. Major surgery or significant traumatic injury within 4 weeks prior to study entry.
7. Use of other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study treatment.
8. Concurrent severe and/or uncontrolled medical conditions (uncontrolled diabetes or infection), known infection with HIV, Hepatitis B or Hepatitis C.
9. Brain metastases, unless previously treated and asymptomatic and not progressive for 2 months.
10. Significant cardiovascular disease (including congestive heart failure).
11. Other malignancy except for treated and cured basal or squamous cell skin cancer, cured in situ cancers, or other cancer from which the patient has been disease-free for ≥ 3 years.
12. Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary.
13. Chronic use of systemic corticosteroid above an accepted physiologic dose (5mg per day of prednisone or equivalent) within 7 days of enrollment except when used as premedication

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CDX-014	CDX-014	During the treatment phase of the study, patients will receive CDX-014 treatment every 3 weeks (RCC or OCCC) or every 2 weeks (RCC) as long as they remain eligible. Patients may be discontinued from CDX-014 treatment based on the results of disease assessments or if experiencing side effects that make study therapy intolerable. The planned dose of CDX-014 depends on the cohort assigned at enrollment.

Primary Outcome Measures

Name	Time	Method
Dose Escalation - Determine Maximum Tolerated Dose (MTD)	Within 21 days after first dose.	Determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of CDX-014 (in mg/kg). MTD will be defined as the highest dose-level where DLT (dose-limiting toxicity) occurs in less than 33% of treated patients.
Cohort Expansion - Assess Objective Response Rate (ORR)	Evaluated every 6-9 weeks following treatment initiation until treatment is discontinued or disease progression, up to 5 years.	Objective Response Rate (ORR) defined as the proportion of patients who achieve radiographic partial or complete response according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guideline.

Trial Locations

Locations (5)

Dana Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

Roswell Park Cancer Institute; 🇺🇸 Buffalo, New York, United States

Huntsman Cancer Institute; 🇺🇸 Salt Lake City, Utah, United States

HonorHealth Research Institute; 🇺🇸 Scottsdale, Arizona, United States

USC/Norris Comprehensive Cancer Center; 🇺🇸 Los Angeles, California, United States